A new analysis reported that continuous glucose monitors (CGMs) reduce overall healthcare costs by roughly 20% for insulin‑dependent diabetes patients—primarily by cutting hospitalizations and ED visits—yet about 80% of eligible patients remain off therapy despite broad insurance coverage. The report, covered by MedCity News, highlights an implementation and access gap between evidence and real‑world adoption. Continuous glucose monitoring tracks interstitial glucose continuously and supports insulin titration and hypoglycemia prevention; the adoption shortfall points to barriers such as patient onboarding, provider workflows, device literacy and reimbursement frictions. Closing the gap could produce measurable cost savings and outcome improvements at health‑system scale.